Skip to main content
SpringerLink
Log in

The burden of atrial fibrillation in the Netherlands

  • Original Article
  • Published:
Netherlands Heart Journal Aims and scope Submit manuscript

Abstract

Background

Atrial fibrillation (AF) is the most common sustained atrial arrhythmia and it is independently associated with an increased morbidity and mortality. As a result of the high prevalence of AF, the economic and clinical impact of the disease is substantial. This study describes the economic and clinical impact of AF in the Netherlands.

Methods

Epidemiological data on AF in the Netherlands were projected on population estimates of the Netherlands in 2009 and combined with data on the cost of AF and its interventions.

Results

Overall prevalence of AF in the Netherlands is 5.5% in the population over 55 years, corresponding to about 250,000 AF patients. The prevalence increases with age, and the mean age of AF patients is 69.3 years. Incidence of AF in the Netherlands varies with age, from 1188 new cases in the age group of 55 to 59 up to 7074 new cases in the age group 75 to 79. Total new cases amounts to 45,085 patients per year in the Netherlands. Total costs of AF in the Netherlands are € 583 million, of which the majority (70%) were accounted for by hospitalisations and in-hospital procedures. Pharmacotherapeutic management of AF totalled € 17 million in the Netherlands in 2009.

Discussion

AF is a serious disease with a high clinical and economic burden, especially due to hospitalisations as a result of cardiovascular events. The number of patients with AF in the Netherlands is considerable and will increase with the ageing population in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–4.

    Article  PubMed  CAS  Google Scholar 

  2. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N–9N.

    Article  PubMed  CAS  Google Scholar 

  3. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359–64.

    Article  PubMed  Google Scholar 

  4. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled ‘research perspectives in atrial fibrillation’. Europace. 2009;11(7):860–85.

    Article  PubMed  Google Scholar 

  5. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.

    Article  PubMed  Google Scholar 

  6. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422–34.

    Article  PubMed  Google Scholar 

  7. McBride D, Mattenklotz AM, Willich SN, et al. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health. 2008;12(2):293–301.

    Article  PubMed  Google Scholar 

  8. Moeremans K, Aliot E, de Chillou C, et al. Second line pharmacological management of paroxysmal and persistent atrial fibrillation in France: a cost analysis. Value Health. 2000;3(6):407–16.

    Article  PubMed  CAS  Google Scholar 

  9. Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004;90(3):286–92.

    Article  PubMed  CAS  Google Scholar 

  10. Reynolds MR, Essebag V, Zimetbaum P, et al. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol. 2007;18(6):628–33.

    Article  PubMed  Google Scholar 

  11. Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace. 2008;10(4):403–11.

    Article  PubMed  Google Scholar 

  12. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Eur Heart J. 2010;31(19):2369–429.

    Article  PubMed  Google Scholar 

  13. Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–52.

    PubMed  CAS  Google Scholar 

  14. Rho RW, Page RL. Asymptomatic atrial fibrillation. Prog Cardiovasc Dis. 2005;48(2):79–87.

    Article  PubMed  Google Scholar 

  15. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70.

    Article  PubMed  CAS  Google Scholar 

  16. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.

    Article  PubMed  CAS  Google Scholar 

  17. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.

    Article  PubMed  CAS  Google Scholar 

  18. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27(10):1760–4.

    Article  PubMed  CAS  Google Scholar 

  19. Sandercock P, Bamford J, Dennis M, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ. 1992;305(6867):1460–5.

    Article  PubMed  CAS  Google Scholar 

  20. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115–9.

    Article  PubMed  Google Scholar 

  21. Kaarisalo MM, Immonen-Räihä P, Marttila RJ, et al. Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. Stroke. 1997;28(2):311–5.

    Article  PubMed  CAS  Google Scholar 

  22. Efremidis M, Pappas L, Sideris A, et al. Management of atrial fibrillation in patients with heart failure. J Card Fail. 2008;14(3):232–7.

    Article  PubMed  Google Scholar 

  23. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920–5.

    Article  PubMed  Google Scholar 

  24. Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2008;29(9):1181–9.

    Article  PubMed  Google Scholar 

  25. Conen D, Osswald S, Albert CM. Epidemiology of atrial fibrillation. Swiss Med Wkly. 2009;139(25–26):346–52.

    PubMed  CAS  Google Scholar 

  26. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol. 2003;91(10A):9G–14G.

    Article  PubMed  Google Scholar 

  27. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–53.

    Article  PubMed  Google Scholar 

  28. Reynolds MR, Ellis E, Zimetbaum P. Quality of life in atrial fibrillation: measurement tools and impact of interventions. J Cardiovasc Electrophysiol. 2008;19(7):762–8.

    Article  PubMed  Google Scholar 

  29. Kang Y. Relation of atrial arrhythmia-related symptoms to health-related quality of life in patients with newly diagnosed atrial fibrillation: a community hospital-based cohort. Heart Lung. 2006;35(3):170–7.

    Article  PubMed  Google Scholar 

  30. Howes CJ, Reid MC, Brandt C, et al. Exercise tolerance and quality of life in elderly patients with chronic atrial fibrillation. J Cardiovasc Pharmacol Ther. 2001;6(1):23–9.

    Article  PubMed  CAS  Google Scholar 

  31. Reynolds MR, Lavelle T, Essebag V, et al. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J. 2006;152(6):1097–103.

    Article  PubMed  Google Scholar 

  32. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74(3):236–41.

    Article  PubMed  CAS  Google Scholar 

  33. Nederlands Huisartsen Genootschap. NHG-standaard atriumfibrilleren M79. 2009. Available from: http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M79_svk.htm. Accessed 23 Dec 2009.

  34. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109(12):1509–13.

    Article  PubMed  Google Scholar 

  35. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33.

    Article  PubMed  CAS  Google Scholar 

  36. Burkhardt JD, Natale A. New technologies in atrial fibrillation ablation. Circulation. 2009;120(15):1533–41.

    Article  PubMed  Google Scholar 

  37. Fisher JD, Spinelli MA, Mookherjee D, et al. Atrial fibrillation ablation: reaching the mainstream. Pacing Clin Electrophysiol. 2006;29(5):523–37.

    Article  PubMed  Google Scholar 

  38. Ehrlich JR, Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs. 2009;69(7):757–74.

    Article  PubMed  CAS  Google Scholar 

  39. Gezondheid en zorg in cijfers 2009. Centraal Bureau voor de Statistiek. Dec 2009. Available from: http://www.cbs.nl/nl-NL/menu/themas/gezondheid-welzijn/publicaties/publicaties/archief/2009/2009-c156-pub.htm. Accessed 5 Jan 2010.

  40. College voor Zorgverzekeringen. www.medicijnkosten.nl. Accessed 5 Jan 2010.

Download references

Funding

This study was funded by Sanofi-Aventis. The authors were independent from Sanofi-Aventis in the conduct and the reporting of this study.

Author information

Authors and Affiliations

  1. Pharmerit International, Marten Meesweg 107, 3068 AV, Rotterdam, the Netherlands

    H. E. Heemstra & M. Meijboom

  2. Population Health Research Institute, Hamilton Health Sciences, McMaster University, 237 Barton Street East, L8L 2X2, Hamilton, Ontario, Canada

    R. Nieuwlaat

  3. Maastricht University Medical Centre, Maastricht, the Netherlands

    H. J. Crijns

Authors
  1. H. E. Heemstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Nieuwlaat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Meijboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. J. Crijns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. E. Heemstra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heemstra, H.E., Nieuwlaat, R., Meijboom, M. et al. The burden of atrial fibrillation in the Netherlands. Neth Heart J 19, 373–378 (2011). https://doi.org/10.1007/s12471-011-0175-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12471-011-0175-4

Keywords

Search

Navigation